雷利度胺治疗骨髓增生异常综合征的研究进展

Research advances on lenalidomide for the treatment of myelodysplastic syndromes

可用于治疗骨髓增生异常综合征（MDS）的药物十分有限，而且很多类型的MDS预后较差，近年来，雷利度胺开始得到大家的关注。目前，雷利度胺已被美国食品与药物管理局（FDA）批准用于治疗国际预后评分系统（IPSS）评分中低危／中危-1且核型为5q31-伴或不伴其他细胞遗传学异常的MDS。但其作用机制仍不清楚。现有研究发现，雷利度胺对其他类型的MDS也有较好的疗效，或可推广应用于其他类型MDS的治疗。

The drugs used in myelodysplastic syndrome（MDS） are quite limited, and the prognosis of some types of MDS is worse. Recently, lenalidomide has gotten people＂ s attentions. Lenalidomide has been approved for the treatment of International Prognostic Scoring System （IPSS）-classified low- or intermediate-1- risk MDS associated with chromosome 5q31 deletion, with or without additional cytogenetic abnormalities. However, the mechanism of action of lenalidomide is still unclear. There are some research findings indicated that lenalidomide also has effect on others types of MDS, suggesting that it can be used more widely. The latest studies about efficacies of lenalidomide on MDS are reviewed in this article.